Palvella Therapeutics, Inc. (PVLA)
138.96
+7.62
(+5.80%)
USD |
NASDAQ |
Oct 09, 16:00
138.96
0.00 (0.00%)
After-Hours: 20:00
Palvella Therapeutics Net Income (Quarterly) : -21.87M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -21.87M |
| March 31, 2026 | -15.77M |
| December 31, 2025 | -12.71M |
| September 30, 2025 | -11.34M |
| June 30, 2025 | -9.471M |
| March 31, 2025 | -8.185M |
| September 30, 2024 | -6.775M |
| June 30, 2024 | -4.172M |
| March 31, 2024 | -2.536M |
| December 31, 2023 | -4.584M |
| September 30, 2023 | -10.75M |
| June 30, 2023 | 3.976M |
| March 31, 2023 | -13.18M |
| December 31, 2022 | -8.102M |
| September 30, 2022 | -9.736M |
| June 30, 2022 | -10.34M |
| March 31, 2022 | -5.101M |
| December 31, 2021 | -9.532M |
| September 30, 2021 | -16.54M |
| June 30, 2021 | -15.50M |
| March 31, 2021 | -4.172M |
| December 31, 2020 | -14.40M |
| September 30, 2020 | -14.28M |
| June 30, 2020 | -4.95M |
| March 31, 2020 | -3.597M |
| Date | Value |
|---|---|
| December 31, 2019 | -0.771M |
| September 30, 2019 | -2.592M |
| June 30, 2019 | -11.76M |
| March 31, 2019 | -10.35M |
| December 31, 2018 | -11.68M |
| September 30, 2018 | -6.153M |
| June 30, 2018 | -0.203M |
| March 31, 2018 | -8.714M |
| December 31, 2017 | 7.490M |
| September 30, 2017 | -7.059M |
| June 30, 2017 | -10.08M |
| March 31, 2017 | -7.994M |
| December 31, 2016 | -6.559M |
| September 30, 2016 | -6.196M |
| June 30, 2016 | -5.883M |
| March 31, 2016 | -4.161M |
| December 31, 2015 | -2.902M |
| September 30, 2015 | -3.922M |
| June 30, 2015 | -3.53M |
| March 31, 2015 | -3.705M |
| December 31, 2014 | -4.166M |
| September 30, 2014 | -2.022M |
| June 30, 2014 | -2.882M |
| March 31, 2014 | -0.7799M |
| December 31, 2013 | 0.9069M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Design Therapeutics, Inc. | -20.16M |
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
| Anika Therapeutics, Inc. | 3.309M |
| BioCryst Pharmaceuticals, Inc. | 78.40M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 21.87M |
| EPS Diluted (Quarterly) | -1.523 |
| Enterprise Value | 1.663B |
| Earnings Yield | -3.48% |
| Normalized Earnings Yield | -3.460 |